Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

✍ Scribed by Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John F Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew P Krivoshik; Sari H Enschede; Rod A Humerickhouse

• Book ID: 117785514
• Publisher: The Lancet
• Year: 2010
• Tongue: English
• Weight: 364 KB
• Volume: 11
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/s1470-2045(10)70261-8